Filgrastim is a Recombinant Protein owned by Amgen, and is involved in 39 clinical trials, of which 32 were completed, and 7 are ongoing.
Filgrastim binds to the G-CSF receptor, which controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. It also stimulates the bone marrow for neutrophils production and decrease their maturation time. Filgrastim acts to raise the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a decrease in duration of the neutropenic phase.
The revenue for Filgrastim is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Filgrastim NPV Report.
Filgrastim (Neupogen, Gran, Granulokine, Grasin, Neupogen Novum) is recombinant-methionyl human granulocyte colony-stimulating factor (“G-CSF”). It is formulated as solution for intravenous and subcutaneous administration. It is indicated to reduce the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. It is employed for reducing the neutrophil time recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML and indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis in Blood Progenitor Cell Collection and Therapy. In addition to above mention indication it is used for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia in patients with severe chronic Neutropenia. It stimulates the release of neutrophils from bone marrow storage pools and decrease their maturation time. It is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome). Neupogen is the first rHuG-CSF to be licensed to treat neutropenia in people with advanced HIV infection. Neupogen is also indicated for the treatment of acute radiation injury.
Filgrastim was under development for myelodysplastic syndrome.
Kyowa Kirin Overview
Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.
Quick View – Filgrastim
|Highest Development Stage|